Evaluation of multiple inhibitors on different hdac complexes shows complex-dependent inhibition profiles, highlighting the role of inositol phosphate.
Class I histone deacetylases regulate gene transcription and are established therapeutic targets. HDAC1-3 form the catalytic subunit in several distinct multiprotein complexes; however, HDAC inhibitors are rarely studied in the context of these complexes. We evaluated multiple inhibitors, using seven HDAC complexes, and found that the inhibition profiles were highly complex-dependent, despite targeting the same enzyme. We also investigated the effect of the allosteric regulator inositol phosphate on these inhibitors. We observed very large, complex-selective reductions in the potency of benzamides bearing a "foot-pocket group", proposed to be selective for HDAC1/2. The potencies of these compounds are likely to be profoundly different in vivo compared with in vitro potencies in the absence of inositol phosphates. Our findings are supported by cell-based assays evaluating histone acetylation and HDAC degradation, highlighting the importance of evaluating HDACi in the context of HDAC complexes and inositol phosphates.
No takes yet. Share an insight, caveat, or question.
Pytel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: